tbuckley/cabot-search huggingface dataset:
FRI0677 Prevalence and serological profile of anti-dfs70 positive subjects: data from a routine ana cohort
Authors: T. Carbone, V. Pafundi, G. Tramontano, M. Gilio, C. Esposito, M. C. Padula, A. A. Padula, S. D'Angelo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Anti-Dense Fine Speckled 70 (DFS70) antibodies are a common finding in clinical laboratory referrals. High prevalence of DFS70 autoantibodies in healthy population and usual negative association with Antinuclear Antibody (ANA)-associated autoimmune rheumatic diseases were reported. <h3>Objectives:</h3> The aim of this study was to evaluate the prevalence of anti-DFS70 antibodies in a routine diagnostic laboratory setting and their association with other circulating serum autoantibodies. <h3>Methods:</h3> Consecutive sera submitted for ANA screening were analyzed for anti-DFS70 antibodies by indirect immunofluorescence (IIF) (n=3175, 1030 men and 2145 women) then confirmed by Immunoblotting. IIF DFS70 positive adult patients were recruited previous written consent and tested for the following autoantibodies: anti-ENA, anti-dsDNA, -anti-TPO, anti-TG, anti-tTg, aCL, anti-PCA, AMA, ASMA, anti-LKM, anti-MPO, anti-PR3 and ASCAs. <h3>Results:</h3> The prevalence of anti-DFS70 antibodies was 1.7% (n= 55) in the whole population and 4.6% in the ANA-positive samples. Comparison between DFS70 IIF and Immunoblotting showed an excellent correlation between the two methods (R=0.99). Analysis of anti-DFS70 antibodies titers distribution revealed that 63% of the total cohort showed high titers (³1:640). Gender difference (female: male, 4:1) was observed in anti-DFS70 positive group and in anti-DFS70 negative/ANA positive group. The prevalence of anti-DFS70 positive female (2.1%, 45/2145) was statistically significant higher than males (1.0%, 10/1030) (p&lt;0.05). The comparison among referring sources evidenced a prevalence of anti-DFS70 positive subjects from Endocrinology Department (9.1% versus 2.6% from Haematology, 2.1% from outpatients, 1.6% from Neurology, 1.2% from Internal Medicine, 1% from Cardiology, 0.6% from Rheumatology). Of note, our data evidenced isolated reactivity of anti-DFS70 autoantibodies in males group, while 51% of females showed concomitant disease-marker autoantibodies. <h3>Conclusions:</h3> We found a prevalence of anti-DFS70 antibodies in adult sera from routine ANA cohort of 1.7%. The serological profile of DFS70-positive females required further investigations in order to define the presence of serum autoantibodies. Anti-DFS70 reactivity in male population may represent an exclusive biomarker predicting the absence of other autoantibodies. <h3>Acknowledgements:</h3> The authours would like to express their expecial appreciation and thanks to Prof. Ignazio Olivieri who died on July 28th, 2017. He was an example of strenght and tenacity with a contagious enthusiasm for a rigorous scientific research. <h3>Disclosure of Interest:</h3> None declared
SP0155 Nutrition – how to talk about it
Authors: V. Krafft
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> When it comes to the subject of nutrition and rheumatism, particularly in relation to inflammatory rheumatism, opinions are sharply divided. Holistically oriented physicians and therapists believe that a change in diet can replace medication in the treatment of chronic inflammation and they thus pursue the goal of reducing the need for medication through an anti-inflammatory diet. Rheumatologists by contrast staunchly defend drug therapy and still approach the subject of nutrition with great reserve, disinterest, or even reject its effects out of hand. Some warn that patients who stray from a balanced diet with a mix of foods may risk nutritional deficiencies. These opposing views leave many of those affected by rheumatism unsure of how to approach nutrition. Can a change in diet really help alleviate the symptoms of inflammatory rheumatism? Which diet rules can I trust? And what's more: How do I speak about it with my rheumatologist? Will he advocate a change in diet and view it as part of my arthritis therapy – or see it merely as a supporting measure, quite a nice idea but without any therapeutic value? Anyone wanting to provide rheumatism patients with some guidance in this regard must ward against possible bias. The Swiss League against Rheumatism makes sure its communications on this controversial issue take into account the whole spectrum of existing medical pluralism. On the question of nutritional benefits, it thus provides information from the point of view of conventional medicine as well as that of complementary medicine and all the shades in between. Objectives of the Swiss League against Rheumatism The Swiss League against Rheumatism endeavours on the one hand to ensure that its communication about nutrition is not one-sided but rather presents the different viewpoints. On the other hand, those affected should be given access to knowledge that can help them to form their own opinion. To achieve these goals, the Swiss League against Rheumatism continually invests human and financial resources into research on this topic, interviews and exchanges with experts, as well as ongoing updates of their contributions. <h3>Communication channels</h3> The Swiss League against Rheumatism informs people about the topic of nutrition through the following communication channels: Website Facebook Brochures Lectures The main focus is on articles on the website. Standpoint of the Swiss League against Rheumatism The Swiss League against Rheumatism includes the subject of nutrition in its communications because there is a great need for information among those affected. The Swiss League against Rheumatism itself takes no position for or against a described measure but rather only makes recommendations based on scientific criteria. On the basis of these scientific criteria, it can be assumed that nutrition, in particular a Mediterranean diet, can have a "positive influence" on various rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
FRI0536 Pregabalin efficacy in treatment of chronic pain in patients with knee osteoarthritis
Authors: E. Filatova, E. Turovskaya, L. Alekseeva
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Modern methods of treatment of osteoarthritis have mainly anti-inflammatory action. A few studies show the effectiveness of centrally acting drugs for chronic pain inosteoartritis (OA) of the knee. <h3>Objectives</h3> To study the efficacy of Pregabalin in treatment of chronic pain in patients with knee OA. <h3>Methods</h3> The study involved 60 female patients with knee OA having neuropathic pain component (NPC; DN4 &gt;4). Mean age 59.82±4.46 y (min 49, max 65 years). All patients were randomly divided into two groups to be treated with 2 therapeutic regimens: aceclofenac +pregabalin (Group I) or aceclofenac (Group II) for 5 weeks (3 visits). All patients were subjected to clinical and neurological examination, total WOMAC score assessment, verification of neuropathic pain (NP) (questionnaire DN4 and Pain DETECT), and VAS pain intensity assessment at rest. <h3>Results</h3> The therapy was successful in both groups with respect to WOMAC score [figure 1] (Group I – 1385,30±365,83 vs 1034,70±402,37 vs 886,64±456,31; Group II – 1206,04±358,72 vs 1016,45±428,52 vs 976,55±408,02 respectively, p=0.01). Significant reduction of pain intensity at rest was documented in both groups [figure 2]. Group I 61,60±14.91 vs 45,34±16,14 vs 36,24±18,09; Group II 56,07±22,58 vs 44.86±18.68 and vs of 41.96±of 24.04, p=0.01, respectively). Therapeutic regimens in both groups had positive impact on NPC based on DN4 questionnaire and Pain DETECT scores. However, a combination of a NSAID with anticonvulsants agent (pregabalin) resulted in a more pronounced effect. Changes in DN4 values in Group I (visit1/visit3) were: 5.97±1,24/2,97±1,83 p=0.001; and in Pain DETECT values – 17,93±3,87/9,34±6,18, p=0.001; while in Group II DN4 scores were 5,35±0,93/3,79±2,29, p=0.001; and Pain DETECT – 15,03±5,26/12,24±6,29 p=0.02. [figures 3–4] <h3>Conclusions</h3> Complex therapy with the use of Pregabalin in patients with OA of the knee, with signs of NPC, allows not only effectively reduce pain intensity and improve functional activity of patients and, consequently, the quality of life. <h3>Disclosure of Interest</h3> None declared
Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study
Authors: Jin-Seok Park, Byung Wook Bang, Su Jin Hong, Eunhye Lee, Kye Sook Kwon, Hyung Kil Kim, Yong Woon Shin, Don Haeng Lee
Journal: Endoscopy (2019)

Abstract Background A new hemostatic adhesive powder (UI-EWD) has been developed to reduce the high re-bleeding rates associated with the currently available hemostatic powders. The current study aimed to assess the efficacy of UI-EWD as a salvage therapy for the treatment of refractory upper gastrointestinal bleeding (UGIB). Methods A total of 17 consecutive patients who had failed to achieve hemostasis with conventional endoscopic procedures and had undergone treatment with UI-EWD for endoscopic hemostasis in refractory UGIB were prospectively enrolled in the study. We evaluated the success rate of initial hemostasis and rate of re-bleeding within 30 days. Results All patients underwent successful UI-EWD application at the bleeding site. Initial hemostasis occurred in 16/17 patients (94 %). Re-bleeding within 30 days occurred in 3/16 patients (19 %) who had achieved initial hemostasis. In the second-look endoscopy after 24 hours, hydrogel from UI-EWD was found attached at the bleeding site in 11/16 patients (69 %). Conclusion UI-EWD has a high success rate for initial hemostasis in refractory UGIB and shows promising results in the prevention of re-bleeding.
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Authors: Stephen M. Ansell, Monique C. Minnema, Peter Johnson, John M. Timmerman, Philippe Armand, Margaret A. Shipp, Scott J. Rodig, Azra H. Ligon, Margaretha G.M. Roemer, Nishitha Reddy, Jonathon B. Cohen, Sarit Assouline, Michelle Poon, Manish Sharma, Kazunobu Kato, Selda Samakoglu, Anne Sumbul, Andrew Grigg
Journal: Journal of Clinical Oncology (2019)

Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory DLBCL. Methods In this phase II, open-label study, patients with relapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT received nivolumab 3 mg/kg every 2 weeks. We assessed the efficacy and safety of nivolumab as well as genetic alterations of 9p24.1. Results Among 121 treated patients, patients in the auto-HCT–failed cohort (n = 87) received a median of four nivolumab doses and a median of three doses were administered to those in the auto-HCT–ineligible cohort (n = 34). At a median follow-up of 9 months in the auto-HCT–failed cohort and 6 months in the auto-HCT–ineligible cohort, independently assessed objective response rates were 10% and 3%, and median durations of response were 11 and 8 months, respectively. Median progression-free survival and overall survival were 1.9 and 12.2 months in the auto-HCT–failed cohort and 1.4 and 5.8 months in the auto-HCT–ineligible cohort respectively. All three patients with complete remission—3% of the auto-HCT–failed cohort—had durable response (11 or more, 14 or more, and 17 months). Treatment-related grade 3 and 4 adverse events were reported in 24% of patients. The most common were neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%). Of all evaluable samples for 9p24.1 analysis, 16% exhibited low-level copy gain and 3% had amplification. Conclusion Nivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for auto-HCT or who experienced failure with auto-HCT. Genetic alterations of 9p24.1 are infrequent in DLBCL.
SAT0246 At which point and for which reasons are oral mtx formulations switched to injectable ones in ra patients? combined results from 3 independent observational and clinical trials
Authors: R.-M. Flipo, A. Saraux, C. Hudry, C. Gaujoux-Viala, E. Senbel, S. Tropé, E. Zinovieva, H. Herman-Demars
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy and safety in case of insufficient response or poor tolerance of oral formulations. Few data are available considering the timepoint at which the route of administration is changed in current practice. <h3>Objectives:</h3> The objective of this work was to investigate across 3 independent trials if there was a consistency in patterns of MTX oral -&gt;injectable switches in terms of RA characteristics, MTX dosages (before and after the switch) and reasons of passage. <h3>Methods:</h3> Three trials were considered for this work: 1/STRATEGE (observational study designed to investigate the therapeutic strategies used in current practice in RA patients insufficiently responding to initial MTX monotherapy), 2/APRiM (observational study aimed to investigate the treatment adherence of RA patients switching from oral to injectable MTX or between two different MTX prefilled syringes) and 3/SELFi (phase III randomized trial aiming to compare a new MTX autoinjector to the historical MTX prefilled syringe in terms of treatment adherence and functional capacity in RA patients at 6 months). In all three studies we selected baseline data concerning patients switching from oral to injectable MTX at the inclusion visit. <h3>Results</h3> Consistent data were observed across the three considered trials concerning the oral/injectable MTX switch. It occurs after about 3 years of treatment, at a DAS28 of 4 and at an average dose of 15 mg/wk (which is consistent with bioavailability data shown before). In most situations, MTX dosage is unchanged or very slightly raised at the switch timepoint. The main switch reasons were "non-achievement of treatment target" and "RA worsening", the safety reasons were mentioned only in 5% of cases. <h3>Conclusions:</h3> Our work showed a consistent pattern across 3 independent trials concerning the oral/injectable MTX switch. It generally occurs at 15 mg/wk, the new injectable dosage being either unchanged or very slightly raised as compared to the last oral one. Surprisingly, the MTX route of administration seems to be modified mostly for efficacy reasons, safety issues being anecdotal. <h3>Reference</h3> 1Schiff MH, et al. Ann Rheum Dis2014. <h3>Disclosure of Interest:</h3> R.-M. Flipo Consultant for: Nordic Pharma, A. Saraux Consultant for: Nordic Pharma, C. Hudry Consultant for: Nordic Pharma, C. Gaujoux-Viala Consultant for: Nordic Pharma, E. Senbel Consultant for: Nordic Pharma, S. Tropé Consultant for: Nordic Pharma, E. Zinovieva Employee of: Nordic Pharma, H. Herman-Demars Employee of: Nordic Pharma
AB1298 Prevalence of rheumatic diseases in colombia by city
Authors: J. Londono, F.M. Cuervo, J.C. Rueda, E.L. Saldarriaga, I. Angarita, I. Peláez, E. Forero, J. Ramirez, C. Toro, A. Santos
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Knowledge of the prevalence of rheumatic diseases allows us to design public health strategies for their comprehensive care and reduction of the costs derived from the potential complications of these diseases. <h3>Objectives</h3> To describe and compare the prevalence of rheumatic disease between six cities from Colombia. <h3>Methods</h3> The study was developed according the COPCORD epidemiological strategy designed for the identification, prevention and control of rheumatic diseases in developing countries. A cross-sectional analytical study including individuals older than 18 years was designed with a calculated sample size of 6528 people (2336 from Bogotá, 1220 from Medellín and Cali each, 746 from Barranquilla, from Bucaramanga and Cúcuta each one). Prevalence of each rheumatic disease was compared between the evaluated cities from Colombia. <h3>Results</h3> A total of 6693 individuals from six cities of Colombia were evaluated. The average age was 46,40±18,35 and 4283 (64%) individuals were women. The cities with the highest frequency of positive COPCORD population were Bogotá 36,6% (n=1813), Cali 19,1% (n=945) and Medellín 15,9% (n=789). <b>Abstract AB1298 – Figure 1</b> The majority of musculoskeletal pain manifested by the population correspond to non-specific muscular discomfort (MMNE). Osteoarthritis (OA) is the most prevalent rheumatic disease (10,81%, 95% CI, 9,68–12,06%). Mechanical low back pain was the most frequent disease in Barranquilla, with a prevalence of 11,91%, mainly in men 15,9% (95% CI, 11,24–21,92%). Regarding to rheumatoid arthritis (RA) it was more prevalent in women, between 40 and 59 years. It was found to be more prevalent in Bogotá (2,8%, 95% CI, 1,8%–4,1%), Cali (4,2%, 95% CI, 2,4–7,3%) and Barranquilla (1,5%, 95% CI, 0,65–3,23%). <b>Table 1.</b> <i>COPCORD*: Community Oriented Program for Control of Rheumatic</i> Diseases <h3>Conclusions</h3> Prevalence of rheumatic diseases is higher in the cities of Bogotá, Cali and Medellin. In Bogotá, Cali and Barranquilla, RA was more prevalent. Low back pain was found to be more prevalent in Barranquilla. The hypothesis is that ethnic diversity of Colombia could explain the difference in prevalence of the rheumatic disease among separate regions. <h3>Disclosure of Interest</h3> None declared
SAT0022 Mir-15a/16 suppress inflammatory response and cell invasion and migration in fibroblast-like synoviocytes in rheumatoid arthritis via targeting sox5
Authors: W. Tan, Q. WU, A. Luo, Y. Wei, F. Wang, M. Zhang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Aberrant expressions of miRNAs play a critical role in the inflammatory and immune response in rheumatoid arthritis (RA). The microRNA cluster which encodes for miR-15a and miR-16, located at 13q14.3. Both these microRNAs have been implicated in the pathogenesis of many diseases, but little is known of their role in RA. <h3>Objectives</h3> In this study, we aim to investigate the underlying molecular mechanisms of MiR-15a/16 in RA, which will provide new insight into understanding the pathogenesis of RA and identifying novel therapeutics targets for this disease. <h3>Methods</h3> The expression of MiR-15a/16 in the peripheral blood mononuclear cell (PBMC) and synovium from RA, osteoarthritis (OA) and healthy controls (HC) was determined by RT-qPCR and Western blotting. Mimics of MiR-15a/16 were transfected into the human rheumatoid fibroblast-like synoviocytes (FLS) MH7A cell line. The effect of MiR-15a/16 on proinflammatory cytokines expression, migration and invasion of FLS was detected by RT-qPCR, transwell and F-actin staining. The potentially target gene of miR-15a/16 was predicted by bioinformatics analysis. The 3′UTR of Sox5 containing wild-type or mutated miR-15a/16 binding sites was cloned to the downstream of a luciferase vector and transfected into MH7A, respectively. <h3>Results</h3> There is no significant difference of MiR-15a/16 expression in PBMC in RA and HC at baseline. However, the MiR-15a/16 expression is lower in PBMC from non-responders (defined DAS28 changes&lt;1.2 after 3 months DMARDs therapy) than those in responders after 3 months DMARDs therapy. The levels of MiR-15a/16 expression were significant decreased in the synovium from RA patients, as compared with OA patients. Transfection of MH7A with MiR-15a and 16 mimic suppressed IL-1b, TNFa, IL-17 expression, decreased cell migration and invasion and affected the cytoskeletal reorganisation in RA-FLS. We co-transfected MH7A with luciferase-reporter constructs with either wild-type or mutated miR-132 or miR-15a/16 mimics. Luciferase assay showed that either miR-15a or 16 reduced the luciferase intensity of Sox5 3′UTR. However, mutated miR-15a/16 alleviated the inhibitory effect of miR-15a/16 on the intensity of Sox5 3′UTR. To determine whether Sox5 mediates the roles of miR-15a/16 in cell migration and invasion, we constructed recombinant Adenovirus SOX5 recombinant Adenovirus SOX5 overexpressing vector. We then found that overexpression of Sox5 restored the cell invasion, and migration in MH7A that were inhibited by and miR-15a/16. <h3>Conclusions</h3> In conclusion, our data indicate that MiR-15a/16 play an important role in inflammatory response and cell invasion and migration in RA-FLS by directly targeting Sox5, and imply that these miRNAs have potential as therapeutic targets for RA. <h3>Disclosure of Interest</h3> None declared
OP0337 Association between metabolic syndrome and trajectories of knee pain: a 10.7-year follow-up study
Authors: F. Pan, J. Tian, F. Cicuttini, C. Ding, G. Jones
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Metabolic syndrome (MetS) has been suggested as having a role in the pathogenesis of osteoarthritis (OA). However, no study has assessed whether MetS and its components are associated with knee pain and its change over time. <h3>Objectives</h3> To identify distinct trajectories of MSP over 10.7 years in an older population, and to examine risk factors for identified trajectories. <h3>Methods</h3> 1099 participants (mean age 63 years) from the population-based Tasmanian Older Adult Cohort study were recruited at baseline. 875, 768 and 563 participants attended years 2.6, 5.1 and 10.7 follow-up, respectively. Demographic, psychological, lifestyle and comorbidities data were obtained at baseline. Knee radiographic OA was assessed by X-ray at baseline. Group-based trajectory modelling was applied to identify distinct trajectories of MSP. Multi-nominal logistic regression was used for the analyses with adjustment for potential confounders. <h3>Results</h3> 985 participants were included for the analyses, three pain trajectories were identified: 'Mild pain' (52%), 'Moderate pain' (33%) and 'Severe pain' (15%) with 32% of participants having Mets. MetS was significantly associated with increased risk of both 'Moderate pain' (relative risk [RR]: 1.47, 95% confidence interval [CI]: 1.10 to 1.96) and 'Severe pain' (2.22, 1.54 to 3.20) relative to 'Mild pain' in univariate analysis. After adjustment for age, sex, smoking, physical activity, emotional problems, comorbidities and radiographic OA, central obesity was associated with increased risk of both 'Moderate pain' (1.70, 1.17 to 2.49) and 'Severe pain' (3.28, 2.16 to 4.98), and MetS and its components (hypertriglyceridemia and low HDL) were only associated with increased risk of 'Severe pain' (p&lt;0.05). However, these associations became weak and non-significant after further adjustment for body mass index (BMI), but hypertension became significantly protective with 'Moderate pain' (0.70, 0.50 to 0.99). Similar associations were found in those with knee OA (RR: 1.70 to 2.75, all p&lt;0.05). <h3>Conclusions</h3> The Mets is predominantly associated with knee pain trajectories through central obesity, and hypertriglyceridemia and low HDL can predict 'Severe pain' trajectory in those with Mets. An unexpected inverse association between hypertension and moderate pain trajectory needs a further investigation, which may reflect an interaction between blood pressure and pain sensitivity in 'Moderate pain' trajectory. <h3>Disclosure of Interest</h3> None declared